Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3K delta) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) Sharman, J., de Vos, S., Leonard, J. P., Furman, R. R., Coutre, S. E., Flinn, I. W., Schreeder, M. T., Barrientos, J. C., Wagner-Johnston, N. D., Boyd, T., Fowler, N. H., Holes, L., Lannutti, B., Johnson, D., Jahn, T. M., Miller, L. L. AMER SOC HEMATOLOGY. 2011: 779–80
View details for Web of Science ID 000299597102382